Silence Therapeutics plc announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high Lp(a) The Company will host a conference call and webcast today at 8 a.m. EDT / 12 p.m. The Company is an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines. On the partnering side, we were pleased for AstraZeneca to enter the clinic